Charles R. Cantor
Founder at DiThera, Inc.
Profile
Charles R.
Cantor was the founder of SelectX Pharmaceuticals, Inc. (founded in 2002) where he served as Chairman from 2002 to 2013.
He was also the founder of Sequenom, Inc. (founded in 1994) where he held the position of Director & Chief Scientific Officer from 1998 to 2011.
Additionally, he is the founder of DiThera, Inc. (founded in 2007) and Retrotope, Inc. (founded in 2006).
Currently, Dr. Cantor holds the position of Director at The Human BioMolecular Research Institute and Clarapath, Inc. He has been a Professor at Boston University since 1992 and a Member of the National Academy of Sciences since 1988.
In the past, Dr. Cantor has held positions as Director-Human Genome Center at Lawrence Berkeley National Laboratory, Director at ExSAR Corp., Chief Scientific Officer at Cellicon Biotechnologies, Inc., and Principal at The Trustees of Columbia University in The City of New York and the University of California, Berkeley.
Dr. Cantor completed his undergraduate degree at The Trustees of Columbia University in The City of New York in 1963 and obtained his doctorate degree from the University of California, Berkeley.
Charles R. Cantor active positions
Companies | Position | Start |
---|---|---|
Boston University | Corporate Officer/Principal | 1991-12-31 |
National Academy of Sciences
National Academy of Sciences Miscellaneous Commercial ServicesCommercial Services National Academy of Sciences operates as a private, nongovernmental institution that advises on issues related to science and technology. It provides independent, objective analysis and advice and conducts other activities to solve complex problems and inform public policy decisions. The firm also encourages education and research, recognize outstanding contributions to knowledge, and increase public understanding in matters of science. The company was founded on March 3, 1863 and is headquartered in Washington, DC. | Corporate Officer/Principal | 1987-12-31 |
The Human BioMolecular Research Institute
The Human BioMolecular Research Institute Miscellaneous Commercial ServicesCommercial Services The Human BioMolecular Research Institute is a research organization that focuses on advancing scientific knowledge in the fields of biochemistry, molecular biology, and biophysics. The non-profit company is based in San Diego, CA. The institute conducts research on a wide range of topics, including cancer, infectious diseases, and neurodegenerative disorders. The company's goal is to develop new treatments and therapies that can improve human health and well-being. | Director/Board Member | - |
DiThera, Inc. | Founder | 2011-05-18 |
Clarapath, Inc.
Clarapath, Inc. Medical SpecialtiesHealth Technology Clarapath, Inc. develops anatomic pathology device. The firm offers routine histology, pathology consultation, whole slide imaging, quantitative image analysis and long term data management services. The company is headquartered in New York, NY. | Director/Board Member | - |
Former positions of Charles R. Cantor
Companies | Position | End |
---|---|---|
The Trustees of Columbia University in The City of New York | Corporate Officer/Principal | - |
Retrotope, Inc.
Retrotope, Inc. Pharmaceuticals: MajorHealth Technology Retrotope, Inc. operates as clinical-stage pharmaceutical company that develops drugs to treat degenerative diseases. It offers drugs and therapies to treat Parkinson’s, Alzheimer’s, mitochondrial myopathies and retinopathies diseases. The company was founded by Charles R. Cantor, Robert J. Molinari, and Mikhail S. Shchepinov in 2006 and is headquartered in Los Altos, CA. | Founder | - |
University of California, Berkeley | Corporate Officer/Principal | - |
Cellicon Biotechnologies, Inc.
Cellicon Biotechnologies, Inc. Pharmaceuticals: MajorHealth Technology Cellicon Biotechnologies, Inc. develops pharmaceutical products. It offers technologies for decoding the protein pathway for the cure of human diseases such as diabetes, arthritis, and cancer. The company was founded in 2002 by Timothy Gardner and is headquartered in Boston, MA | Chief Tech/Sci/R&D Officer | - |
░░░░░░░░ ░░░░░░░░ ░░░░░░░░ ░░░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Training of Charles R. Cantor
The Trustees of Columbia University in The City of New York | Undergraduate Degree |
University of California, Berkeley | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 10 |
---|---|
Sequenom, Inc.
Sequenom, Inc. Medical SpecialtiesHealth Technology Sequenom, Inc. engages in the provision of early patient management information. It develops and commercializes molecular diagnostic testing services that serve women's health and oncology markets. The company was founded by Hubert Koester and Charles R. Cantor in October 09, 1996 and is headquartered in Burlington, NC. | Health Technology |
Cellicon Biotechnologies, Inc.
Cellicon Biotechnologies, Inc. Pharmaceuticals: MajorHealth Technology Cellicon Biotechnologies, Inc. develops pharmaceutical products. It offers technologies for decoding the protein pathway for the cure of human diseases such as diabetes, arthritis, and cancer. The company was founded in 2002 by Timothy Gardner and is headquartered in Boston, MA | Health Technology |
Lawrence Berkeley National Laboratory
Lawrence Berkeley National Laboratory Miscellaneous Commercial ServicesCommercial Services Lawrence Berkeley National Laboratory engages on research of environmental studies, nanoscience, and quantitative biology, physics and nuclear energy. The lab is funded by the U.S. Department of Energy and managed by the University of California. It was founded in 1931 by Ernest Orlando Lawrence and is headquartered in Berkeley, CA. | Commercial Services |
SelectX Pharmaceuticals, Inc.
SelectX Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology SelectX Pharmaceuticals, Inc. engages in the discovery and development of aminoglycoside therapeutics for unmet medical needs. Its advanced program, development candidate SXP2523, is a next generation aminoglycoside antibiotic for drug resistant gram-negative hospital-acquired infections (HAIs); SXP2523 possesses broad spectrum coverage with potency against Pseudomonas, Klebsiella, Acinetobacter, E. coli, and Staphylococcus. The company was founded by Michael G. Chaparian and Charles R. Cantor in 2002 and is headquartered in Boston, MA. | Health Technology |
National Academy of Sciences
National Academy of Sciences Miscellaneous Commercial ServicesCommercial Services National Academy of Sciences operates as a private, nongovernmental institution that advises on issues related to science and technology. It provides independent, objective analysis and advice and conducts other activities to solve complex problems and inform public policy decisions. The firm also encourages education and research, recognize outstanding contributions to knowledge, and increase public understanding in matters of science. The company was founded on March 3, 1863 and is headquartered in Washington, DC. | Commercial Services |
ExSAR Corp.
ExSAR Corp. Pharmaceuticals: MajorHealth Technology ExSAR has offered drug discovery services to pharmaceutical, biotechnology and academic laboratories since its founding in 1997. In 2005, ExSAR initiated a program of collaborative research relationships to discover new therapeutics for the treatment of protein misfolding disorders. The aim is to become the leading drug developer in a rapidly growing $10+ billion market in metabolic and neurodegenerative disorders. Many of these disorders are characterized by mutations which lead to protein misfolding and instability followed subsequently by protein degradation. Many of these diseases currently lack any effective treatment. ExSAR is now a clinical developmental stage company dedicated to identifying, developing and commercializing small-molecule therapeutics for diseases of protein conformation. ExSAR expects to initiate clinical studies for the treatment of Tay Sachs, Sandhoff and Gaucher Diseases. | Health Technology |
The Human BioMolecular Research Institute
The Human BioMolecular Research Institute Miscellaneous Commercial ServicesCommercial Services The Human BioMolecular Research Institute is a research organization that focuses on advancing scientific knowledge in the fields of biochemistry, molecular biology, and biophysics. The non-profit company is based in San Diego, CA. The institute conducts research on a wide range of topics, including cancer, infectious diseases, and neurodegenerative disorders. The company's goal is to develop new treatments and therapies that can improve human health and well-being. | Commercial Services |
DiThera, Inc. | |
Retrotope, Inc.
Retrotope, Inc. Pharmaceuticals: MajorHealth Technology Retrotope, Inc. operates as clinical-stage pharmaceutical company that develops drugs to treat degenerative diseases. It offers drugs and therapies to treat Parkinson’s, Alzheimer’s, mitochondrial myopathies and retinopathies diseases. The company was founded by Charles R. Cantor, Robert J. Molinari, and Mikhail S. Shchepinov in 2006 and is headquartered in Los Altos, CA. | Health Technology |
Clarapath, Inc.
Clarapath, Inc. Medical SpecialtiesHealth Technology Clarapath, Inc. develops anatomic pathology device. The firm offers routine histology, pathology consultation, whole slide imaging, quantitative image analysis and long term data management services. The company is headquartered in New York, NY. | Health Technology |
- Stock Market
- Insiders
- Charles R. Cantor